17,261 trials
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 6; 8; 6; 4 Participants
Recurrent Childhood Anaplastic Astrocytoma · Recurrent Childhood Brain Stem Glioma · Recurrent Childhood Ependymoma
Primary: Relative Phosphorylation of ERBB2 (Molecular Biology Objective) — .21; .50 ratio
Kidney Cancer
Primary: Tumor Burden Reduction Rate (TBRR) — 30; 70 percentage of patients
Essential Tremor
Primary: Normalized Mean Tremor Amplitude for Both Formulations of 64 mg/kg 1-Octanol in Part B — 1; 1; 1.009; 0.901 normalized score on a scale
Atrial Fibrillation
Primary: Dose-response Relationship for QTcF Interval of AZD1305 — 461; 486; 490; 482 ms
Non-Small-Cell Lung Carcinoma
Primary: Overall Objective Response Rate (ORR) — 11.7; 3.8 percentage of participants
Bronchiectasis
Primary: Change From Baseline in Total Bacterial Load in the Sputum at End of Treatment (Day 29). — -2.94; -0.32 log10 of CFU per gram sputum — p=< 0.001
HIV Infections
Primary: Change in Absolute CD4+ Lymphocyte Counts From Baseline (Average of Pre-entry and Entry Values) — 15; 11; 12; 8 cells/mm^3 — p=0.1996
Brain Diseases · Spinal Cord Diseases
Primary: Categorical Visualization Score (CVS) — 1.43; 2.02; 1.98 Scores on a scale — p=0.003
Influenza
Primary: Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain. — 589.8; 933.1 Titers
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change in Intraocular Pressure at Day 1 — -4.16; -4.57; -0.60 mmHg
Diabetes Mellitus, Type II · Fatty Liver
Primary: Insulin Resistance and Glucose Homeostasis — .69; .24; -0.51; .73 mg/kg/min — p=0.040
Leukaemia, Lymphocytic, Chronic
Primary: Number of Participants With a Dose-limiting Toxicity (DLT) — 0 participants
Parkinson Disease
Primary: Change in Stride Length From Baseline — 1.19 CM
Pulmonary Hypertension
Primary: Number of Participants With Pulmonary Arterial Hypertension (PAH) Who Completed the Phase II NCT00046319 Study and Who Experienced Severe Adverse Events (AEs) During…